# PULMONARY HYPERTENSION (PHT)

> PHT defined as PA mean pressure ≥25 mmHg at rest (in future ? ≥20 mmHg based on emerging data _\[_ Lancet Respir Med _2018;6:168\]_)  
> _PA mean_ = _CO_ × _PVR_ + _PA wedge pressure. Trans pulm gradient_ = _PA mean – PA wedge._

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>原因 (Revised WHO Classification)</b> (<span><i>JACC</i> 2013;62:D34</span>)</p></td></tr><tr><td><p><b>Primary pulmonary arterial HTN (PAH)</b> (group 1)</p><p>Precapillary PHT</p><p>PCWP ≤15 mmHg</p><p>↑ transpulm grad</p><p>↑ PVR</p></td><td><p><span>•</span> Idiopathic (IPAH): yearly incidence 1–2 per million; mean age of onset 36 y (♂ older than ♀); ♂:♀ = ~2:1, usually mild ↑ in PAP</p><p><span>•</span> Familial (FPAH)</p><p><span>•</span> Associated conditions (APAH)</p><p><span>•</span> Connective tissue dis.: CREST, SLE, MCTD, RA, PM, Sjögren</p><p><span>•</span> Congenital L→R shunts: ASD, VSD, PDA</p><p><span>•</span> Portopulmonary HTN (? 2° vasoactive substances not filtered in ESLD; ≠ hepatopulmonary syndrome)</p><p><span>•</span> HIV; drugs &amp; toxins: anorexic agents, SSRIs, <small>L</small>-tryptophan</p><p><span>•</span> Pulmonary veno-occlusive disease: ? 2° chemo, BMT; orthopnea, pl eff, CHF, 正常 PCWP; art vasodil. <i>worsen</i> CHF (<span><i>AJRCCM</i> 2000;162:1964</span>)</p><p><span>•</span> Pulmonary capillary hemangiomatosis</p></td></tr><tr><td><p><b>Left heart disease</b> (group 2). ↑ PCWP</p></td><td><p><span>•</span> Left atrial or ventricular (diastolic or systolic) dysfunction</p><p><span>•</span> Left-sided valvular heart disease (eg, MS/MR)</p></td></tr><tr><td><p><b>Lung diseases and/ or chronic hypoxemia</b> (group 3)</p></td><td><p><span>•</span> COPD<span></span>• Alveolar hypoventilation (eg, NM disease)</p><p><span>•</span> ILD <span></span>&nbsp;&nbsp;&nbsp;&nbsp;• Chronic hypoxemia (eg, high altitude)</p><p><span>•</span> Sleep apnea&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Developmental abnormalities</p></td></tr><tr><td><p><b>Chronic thrombo-embolic dis</b> (group 4)</p></td><td><p><span>•</span> Prox or distal PEs; ~1/2 without 臨床h/o PE (<span><i>NEJM</i> 2011;364:351</span>)</p><p><span>•</span> Nonthrombotic emboli (tumor, foreign body, parasites)</p></td></tr><tr><td><p><b>Miscellaneous/ Multifactorial</b> (group 5)</p></td><td><p><span>•</span> Sarcoidosis, histiocytosis X, LAM, schistosomiasis, ESRD</p><p><span>•</span> Compression of pulm vessels (adenopathy, tumor, fibrosing mediastinitis, histoplasmosis, XRT)</p><p><span>•</span> Other: thyroid dis., glycogen storage dis., Gaucher dis, HHT, sickle cell etc, chronic myeloprolif d/o, splenectomy</p></td></tr></tbody></table>

## 臨床表現

• Dyspnea, exertional syncope (hypoxia, ↓ CO), exertional chest pain (RV ischemia)

• Symptoms of R-sided CHF (eg, peripheral edema, RUQ fullness, abdominal distention)

• WHO class: I = asx with ordinary activity; II= sx with ord. activ; III = sx with min activ.; IV = sx at rest

## Physical exam

• PHT: prominent P2, R-sided S4, RV heave, PA tap & flow murmur, PR (Graham Steell), TR

• ± RV failure: ↑ JVP, hepatomegaly, peripheral edema

## Diagnostic studies & workup (_JACC_ 2013;62:D40; _Circ_ 2014;130:1820)

• High-res chest CT: dilat. & pruning of pulm arteries, ↑ RA & RV; 排除 parenchymal lung dis.

• ECG: RAD, RBBB, RAE (“P pulmonale”), RVH (Se 55%, Sp 70%)

• 肺功能: disproportionate ↓ DLco, mild restrictive pattern; 排除 obstructive & restrictive lung dis.

• ABG & polysomnography: ↓ PaO2 and SaO2 (espec with exertion), ↓ PaCO2, ↑ A-a gradient; 排除 hypoventilation and OSA

• TTE: ↑ RVSP (but estimate over/under by ≥10 mmHg in ½ of PHT 病人; _Chest_ 2011;139:988) ↑ RA, RV, & PA; ↑ pressure → interventricular septum systolic flattening (“D” shape) ↓ RV systolic fxn (TAPSE <1.6 cm); TR, PR; 排除 LV dysfxn, MV, AoV, congenital disease

• RHC: ↑ RA, RV, & PA pressures; ✔ L-sided pressures and for shunt

if PAH: 正常 PCWP, ↑ transpulmonary gradient (mean PAP-PCWP >12–15), ↑ diastolic pulmonary gradient (PA diastolic – PCWP >7), ↑ PVR, ± ↓ CO

if 2° to L-heart disease: PCWP (or LVEDP) >15; if PVR 正常 → “passive PHT”; PVR >240 suggests mixed picture: if ↓ PCWP → ↓ PVR, then “reactive” PHT; if no Δ, then “fixed”

• CTA (large/med vessel), V/Q scan (small vessel to 排除 CTEPH), ± pulm angio if ↑ concern

• Labs: ANA (~40% ⊕ in PAH), RF, anti-Scl-70, anticentromere, ESR; LFTs; HIV

• 6-min walk test (6MWT) or cardiopulmonary exercise testing to establish fxnl capacity

## 治療 (_JACC_ 2013;62:25S & 2015;65:1976; _EHJ_ 2016;37:67)

• Principles: 1) prevent & reverse vasoactive substance imbalance and vascular remodeling

2) prevent RV failure: ↓ wall stress (↓ PVR, PAP, RV diam); ensure adeq systemic DBP

• **Supportive**

Oxygen: maintain SaO2 >90–92% (reduces vasoconstriction)

Diuretics: ↓ RV wall stress and relieve RHF sx; _gentle_ b/c RV is preload dependent

Digoxin: control AF, ? counteract neg inotropic effects CCB

Anticoag: not routinely used; ↓ VTE risk of RHF; ? prevention of _in situ_ microthrombi; ? mortality benefit even if in NSR, no RCTs (_Chest_ 2006;130:545)

Supervised exercise training; aggressive apnea/hypoventilatory Rx with CPAP/BiPAP

• **Vasodilators** (ideally right heart catheterization prior to initiation; _NEJM_ 2004;351:1425) _acute vasoreactivity test:_ use inh NO, adenosine or prostacyclin to identify 病人 likely to have long-term response to CCB (⊕ response = ↓ PAP ≥10 mmHg to <40 mmHg with ↑ or stable CO); ~10% 病人 acute responders; no response → still candidate for other vasodilators

<table><colgroup><col> <col></colgroup><tbody><tr><td><p><b>Vasoactive Agents</b></p></td><td><p><b>Comments</b> <span>(data primarily in Group 1; little evidence in 2° PHT)</span></p></td></tr><tr><td><p><b>PDE-5 inhibitor</b></p><p>sildenafil, tadalafil, vardenafil</p></td><td><p>↑ cGMP → vasodilation, ↓ smooth muscle proliferation, ↓ sx, ↑ 6MWT, no data on 臨床outcomes. Often first-line b/c minimal side-effect profile: HA, vision Δ’s, sinus congestion (<span><i>NEJM</i> 2009;361:1864</span>).</p></td></tr><tr><td><p><b>Endothelin receptor antagonists (ERAs)</b> bosentan, ambrisentan, macitentan</p></td><td><p>↓ Smooth muscle remodeling, vasodilation, ↓ fibrosis, ↓ sx, ↑ 6MWT, ↓ worsening PAH or need for prostanoids with trend for ↓ PAH mort (w/ macitentan). Side effects: ↑ LFTs, HA, anemia, edema, teratogen (<span><i>NEJM</i> 2002;346:896; <i>Circ</i> 2008;117:3010; <i>NEJM</i> 2013;369:809</span>).</p></td></tr><tr><td><p><b>IV Prostacyclin</b> epoprostenol (Flolan)</p></td><td><p>Vasodilation, ↓ plt agg, ↓ smooth muscle proliferation; benefits ↑ with time (? vascular remodeling). ↑ 6MWT, ↑ 生活品質, ↓ <b>mortality.</b> Side effects: HA, flushing, jaw/leg pain, abd cramps, nausea, diarrhea, catheter infxn (<span><i>NEJM</i> 1996;334:296 &amp; 1998;338:273; Annals 2000;132:425</span>).</p></td></tr><tr><td><p><b>Prostacyclin analogues</b> [iloprost (inh) treprostinil (IV, inh, SC)] &amp; <b>receptor agonist</b> selexipag (PO)</p></td><td><p>Same mechanism as prostacyclin IV but easier to take, ↓ side effects, and without risk of catheter infxn, ↓ sx, ↑ 6MWT; trend to ↓ 臨床events with iloprost but not treprostinil. Inh Rx with improved V/Q matching. Selexipag ↓ disease prog &amp; hosp by ~40% (<span><i>NEJM</i> 2015;373:2522</span>).</p></td></tr><tr><td><p><b>Soluble guanylate cyclase (sGC) stim</b></p><p>riociguat</p></td><td><p>NO-independent ↑ cGMP → vasodilation, ↓ smooth muscle proliferation, ↓ sx, ↑ 6MWT in PAH; ↓ sx, ↓ PVR, ↑ 6MWT in CTEPH (<span><i>NEJM</i> 2013;369:319 &amp; 330</span>)</p></td></tr><tr><td><p><b>Oral CCB</b></p><p>nifedipine, diltiazem</p></td><td><p>Consider if ⊕ acute vasoreactive response; not 1<sup>st</sup> line b/c side effects: HoTN, lower limb edema</p></td></tr></tbody></table>

• Upfront combination Rx (tadalafil + ambrisentan vs. monotherapy): ↓ sx, ↓ NT-BNP, ↑ 6MWT, ↓ hospitalizations (_NEJM_ 2015;373:834)

• Treat underlying causes of 2° PHT; can use vasodilators, although little evidence

• CTEPH: Rx as above. Pulm endarterectomy potentially curative (_AJRCCM_ 2011;183:1605).

• Refractory PHT: balloon atrial septostomy: R→L shunt causes ↑ CO, ↓ SaO2, net ↑ tissue O2 delivery; lung txp (single or bilateral; heart-lung needed if Eisenmenger physiology)

### Figure 2-5 治療 of PAH (modified from _JACC_ 2013;62:D60 & _EHJ_ 2016;37:67)

![](https://i.imgur.com/ovnCqQP.jpg)

## Management of ICU patient

• Avoid tachyarrhythmias & overly aggressive volume resuscitation

• Caution with vasodilators if any L-sided dysfxn. _Intubation can cause hemodynamic collapse._

• Dobutamine and inhaled NO or prostacyclin

• Consider R-sided mechanical support (_Circ_ 2015;132:536)

• Consider fibrinolysis if acute, refractory decompensation (eg, TPA 100 mg over 2 h)

## Prognosis

• Median survival after dx ~2.8 y; PAH (all 原因): 2-y 66%, 5-y 48% (_Chest_ 2004;126:78–S)

• Poor prognostic factors: 臨床evidence of RV failure, rapidly progressive sx, WHO (modified NYHA) class IV, 6MWT <300 m, peak VO2 <10.4 mL/kg/min, ↑ RA or RV or RV dysfxn, RA >20 or CI <2.0, ↑ BNP (_Chest_ 2006;129:1313)

• Lung transplant: 1-y survival 66–75%; 5-y survival 45–55% (_Chest_ 2004;126:63S)
